Various immunomodulatory drugs are used in the treatment of relapsing-remitting patients with multiple sclerosis (RRMS). The effectiveness of these drugs varies among patient, therefore the clinical decision which
immunomodulatory treatment will be initiated in RRMS patients is currently
arbitrary, based on trial and error. A new laboratory method was developed to individually optimize the immunomodulatory treatment tailored per patient.
This method is of tremendous importance both to the patient and treating
physician for better management of MS
lovebug wrote: Does anybody know if there is a blood test yet that will determine who will benefit from Interferons?
He said a simple, already available blood test could spare many patients the inconvenience and side effects — and spare the health-care system the expense — of a drug that most likely won’t do any good. “The other side of the coin is that beta-interferon, if it’s given only to those who are predisposed to respond to it, could turn out to be a far better drug than we ever imagined.”
Although Steinman and his colleagues do not stand to benefit in any direct way from this work, Stanford University’s Office of Technology Licensing has filed a patent application on the use of the blood test.
Stanford and Pfizer researchers have suggested that IL-7 and IL-17F levels together can help identify up to one-third of nonresponders to interferon therapy for multiple sclerosis. The university has spun out a new company—Atreca Inc.—to develop predictive blood tests.
Interferon-beta caused patients to become far more efficient at making vitamin D in their skin
Interferon-beta only reduced the risk of having an MS attack if patients had sufficient levels of vitamin D in their system
Users browsing this forum: NZer1